Olutasidenib
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Olutasidenib Alone or in Combination With Azacitidine as a Bridge to Transplant in Relapsed/Refractory mIDH1 AML.
Journal: European journal of haematology
Published: May 27, 2026
Differentiation Syndrome in Acute Myeloid Leukemia: Molecular Mechanisms, Clinical Spectrum, and Emerging Therapeutic Paradigms.
Journal: International journal of molecular sciences
Published: December 29, 2025
Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Journal: Advances in therapy
Published: December 17, 2025
The Care and Cure of the Leukemias in 2026.
Journal: American journal of hematology
Published: December 03, 2025
Prognostic Implications and Therapeutic Landscape of IDH1-Mutated AML: An Updated Review of Evidence and Indian Perspective.
Journal: Asian Pacific journal of cancer prevention : APJCP
Published: November 11, 2025
Olutasidenib: an Achilles' heel for IDH1-mutated MDS?
Journal: Blood advances
Published: October 20, 2025
Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.
Journal: Chemistry & biodiversity
Published: October 08, 2025
Chemotherapy in dedifferentiated chondrosarcoma: From neoadjuvant to palliative treatment options.
Journal: Critical reviews in oncology/hematology
Published: September 27, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 25, 2025
Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort.
Journal: Journal of hematology & oncology
Published: July 21, 2025
Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review.
Journal: Cancers
Published: July 11, 2025
Last Updated: 09/26/2026